±³½Ç¼Ò°³

    • home
    • ±³½Ç¼Ò°³
    • ±âÃÊÀÇÇÐ

±âÃÊÀÇÇÐ

  • ÀüÀÓ±³¼ö(ÀÇ°ú´ëÇÐ)
  • ±è±Õȯ
  • Àü°øºÐ¾ß £ü
  • ¿¬¶ôó     £ü (ÀüÈ­) 031-299-6126 / (fax)
  • À̸ÞÀÏ     £ü khkim10@skku.edu

ÁÖ¿ä°æ·Â

  • 1985-1991 ¼­¿ï´ëÇб³ È­Çаú, ÇÐ»ç ¹× ¼®»ç (»ýÈ­ÇÐ)
    1991-1999 ·Ôµ¥±×·ìÁß¾Ó¿¬±¸¼Ò, ¼±ÀÓ¿¬±¸¿ø
    1997-2002 ¿¬¼¼´ëÇб³ »ý¸í°øÇаú, ¹Ú»ç
    2003-2005 Brown University, School of Medicine, ¹Ú»çÈÄ¿¬±¸¿ø
    2006-2019 °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø, Á¶±³¼ö, ºÎ±³¼ö, ±³¼ö
    2020-ÇöÀç ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ, ±³¼ö

ÁÖ¿ä°ü½É¿¬±¸

  • ¹ÙÀÌ·¯½º¼º Áúº´ ¿¬±¸½ÇÀÇ ÁÖ ¿¬±¸ ºÐ¾ß´Â BÇü °£¿°¹ÙÀÌ·¯½º(HBV)¿Í ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º(IAV)¹× ÀÌµé ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ Áúº´ÀÇ ±âÀü°ú Ä¡·áÁ¦ Ÿ°Ù ¹ß±¼ µî ÀÔ´Ï´Ù.
    HBV´Â °£¿°, °£°æº¯, °£¾ÏÀ» ÀÏÀ¸Å°°í, IAV´Â ±Þ¼º È£Èí±â Áúº´À» ÀÏÀ¸Å°´Â ÁÖ¿ä¹ÙÀÌ·¯½ºÀÌÁö¸¸ ¾ÆÁ÷±îÁö µÎ ¹ÙÀÌ·¯½º ¸ðµÎ ¿ÏÀüÇÑ Ä¡·áÁ¦°¡ ¾ø´Â ½ÇÁ¤ÀÔ´Ï´Ù. µû¶ó¼­, º» ¿¬±¸½Ç¿¡¼­´Â ÇØ´ç ¹ÙÀÌ·¯½ºµéÀÇ »ýÈ°»ç ¹× »ç¶÷¼¼Æ÷¿ÍÀÇ »óÈ£ ÀÛ¿ëÀ» ±íÀÌ ÀÖ°Ô ¿¬±¸ÇÔÀ¸·Î½á ¹ÙÀÌ·¯½º¼º °£Áúȯ°ú È£Èí±â Áúº´ÀÇ ±âÀüÀ» ÀÌÇØÇÏ°í ÃÖÁ¾ÀûÀ¸·Î´Â ÀÌµé ¹ÙÀÌ·¯½ºµéÀÇ ¿ÏÀüÇÑ Ä¡·áÁ¦¸¦ °³¹ßÇÏ´Â °ÍÀÔ´Ï´Ù.
    º» ¿¬±¸½ÇÀÇ ÁÖ ¿¬±¸ Å׸¶´Â ´ÙÀ½°ú °°½À´Ï´Ù. 1) Pathogenesis of viral infection, 2) Host immune escape of virus, 3) virus-induced liver and pulmonary diseases, 4) Development of anti-viral drugs.

´ëÇ¥¿¬±¸¾÷Àû

  • 1.Shin GC, Moon SU, Kang HS, et al., & Kim KH*. PRKCSH contributes to tumorigenesis by ive boosting of IRE1 signaling pathway. Nat. Commun. 2019. Jul 1810(1):3185.

    2.Park ES, Byun YH, Park S, et al., & Kim KH*. Co-degradation of interferon signaling factor DDX3 by PB1-F2 as a basis for high virulence of 1918 pandemic influenza. EMBO J. 2019. Apr 12. pii: e99475.

    3.Park ES, Lee AR, Kim DH, et al., & Kim KH*. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019. Feb 19. S0168-8278(19)30120-5.

    4.Kim DH, Park ES, Lee AR, et al., & Kim KH*. Intracellular interleukin-32¥ã mediates antiviral activity of cytokines against hepatitis B virus. Nat. Commun. 2018. Aug 169(1):3284.

    5.Lee AR, Lim KH, Park ES, et al., & Kim KH*. Multiple functions of cFLIP are essential for replication of hepatitis B virus. J Virol. 2018. Jul 3192(16). pii: e00339-18.

    6.Lim KH, Park ES, Kim DH, et al., & Kim KH*. Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5''''-UTR of TRIM22. Gut. 2017. Mar 23. pii: gutjnl-2016-312742.

    7.Shin GC, Kang HS, Lee AR, Kim KH*. Hepatitis B Virus–triggered Autophagy Targets Death Receptor 5 for Degradation to Limit TNFSF10/TRAIL Response. Autophagy. 2016. 12 (12):1󈝼.

    8.Park YK, Park ES, Kim DH, et al., & Kim KH*. Cleaved c-FLIP mediates the antiviral effect of TNF-<alpha> against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol. 2016. Feb64(2):268-277.

    9.Ahn SH, Park YK, et al., & Kim KH*. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014. 88(12):6805.

    10.Park ES, Park YK, Shin C, et al., & Kim KH*. Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator. Hepatology. 2013.58:762-776.